## Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: D30DN

PI Accessory Mutations: K20T • G73GS

PR Other Mutations: I13V • G16GR • E35D • M36I • G40GE • R41K • W42W* • R57RK • I62V • L63P • G68GR • H69K • T74S • G86GR • L89M • G94GS

| Protease Inhibitors | |
|---|---|
| **atazanavir/r (ATV/r)** | Low-Level Resistance |
| **darunavir/r (DRV/r)** | Susceptible |
| **fosamprenavir/r (FPV/r)** | Low-Level Resistance |
| **indinavir/r (IDV/r)** | Low-Level Resistance |
| **lopinavir/r (LPV/r)** | Susceptible |
| **nelfinavir (NFV)** | High-Level Resistance |
| **saquinavir/r (SQV/r)** | Low-Level Resistance |
| **tipranavir/r (TPV/r)** | Susceptible |

**PR comments**

**Major**

- **D30N** is a non-polymorphic mutation NFV-selected mutation that causes high-level resistance to NFV but not to other PIs.

**Accessory**

- **K20T** is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to ATV and LPV.
- **G73S/T/C/A** are common non-polymorphic accessory mutations selected primarily by most PIs. They are associated with minimally reduced susceptibility to each of the PIs.

**Other**

- **T74S** is a PI-selected accessory mutation that is polymorphic in most non-B subtypes.

## Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

*Drug resistance mutation scores of PI:* Download CSV

| Rule | ATV/r | DRV/r | FPV/r | IDV/r | LPV/r | NFV | SQV/r | TPV/r |
|---|---|---|---|---|---|---|---|---|
| K20T | 5 | 0 | 5 | 5 | 0 | 15 | 5 | 0 |
| G73GS | 10 | 0 | 10 | 15 | 5 | 15 | 15 | 0 |
| D30DN | 0 | 0 | 0 | 0 | 0 | 60 | 0 | 0 |
| Total | 15 | 0 | 15 | 20 | 5 | 90 | 20 | 0 |

## Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None

NNRTI Mutations: K103N

RT Other Mutations: E6D • G15GR • M16MI • V35T • M41MI • E44EK • K49R • G51GR • V60I • W71W* • G93GR • G99GE • G112GE • K122E • D123S • I135T • K173S • Q174K • D177E • I178M • V179I • T200A • Q207A • P243A • V245Q • D250E • A272S • K281R • S519N • Q520H • Q524K • K527EQ • E529D • A534S • A534S

| Nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **abacavir (ABC)** | Susceptible |
| **zidovudine (AZT)** | Susceptible |
| **stavudine (D4T)** | Susceptible |
| **didanosine (DDI)** | Susceptible |
| **emtricitabine (FTC)** | Susceptible |
| **lamivudine (3TC)** | Susceptible |
| **tenofovir (TDF)** | Susceptible |

| Non-nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **doravirine (DOR)** | Susceptible |
| **efavirenz (EFV)** | High-Level Resistance |
| **etravirine (ETR)** | Susceptible |
| **nevirapine (NVP)** | High-Level Resistance |
| **rilpivirine (RPV)** | Susceptible |

**RT comments**

**NNRTI**

- **K103N** is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

**Other**

- **V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

## Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for NRTI.*

*Drug resistance mutation scores of NNRTI:* Download CSV

| Rule | DOR | EFV | ETR | NVP | RPV |
|---|---|---|---|---|---|
| K103N | 0 | 60 | 0 | 60 | 0 |

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None

INSTI Accessory Mutations: None

IN Other Mutations: K14R 94% (n=258) • R20K 100% (n=269) • V31I 100% (n=229) • I60M 99% (n=96) • I72V 1.72%, V 27% (n=93) • T112V 100% (n=76) • I113V 100% (n=76) • F121FV 72.50%, V 27% (n=73) • T124A 100% (n=60) • T125A 100% (n=63) • V126F 100% (n=60) • G134N 100% (n=72) • I135V 100% (n=72) • K136Q 100% (n=72) • F139Y 98% (n=64) • V150VG 0.98%, G 44% (n=113) • V201I 99% (n=140) • K211R 99% (n=175) • T218S 99% (n=171) • K219N 99% (n=170) • N222K 100% (n=267) • S230SN N 56%, S 44% (n=225) • L234I 99% (n=146) • I268L 100% (n=253) • S283G 100% (n=129)

| Integrase Strand Transfer Inhibitors | |
|---|---|
| **bictegravir (BIC)** | Susceptible |
| **cabotegravir (CAB)** | Susceptible |
| **dolutegravir (DTG)** | Susceptible |
| **elvitegravir (EVG)** | Susceptible |
| **raltegravir (RAL)** | Susceptible |

**IN comments**

**Other**

- F121Y is a rare nonpolymorphic mutation selected primarily by RAL. It is associated with >10-fold reduced susceptibility to RAL but has minimal if any effect on susceptibility to CAB, DTG, and BIC. F121C is an extremely rare mutation. Preliminary data suggests it may confers high level phenotypic resistance to RAL, EVG, and possibly CAB. **F121V** is an unusual mutation at this position.
- **S230N** is a polymorphism that is not associated with reduced INSTI susceptibility.

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for INSTI.*